Pfizer and BionTech said the vaccine’s efficacy is consistent across age, gender, race, and ethnicity demographics. Its efficacy in adults over 65 years of age is more than 94%.
The U.S. pharmaceutical company and the German biotechnology company added that their COVI-19 vaccine achieved the safety data milestone required by FDA for Emergency Use Authorization (EUA).
Pfizer and BioNTech plan to submit an application for EUA with the FDA within days and share data with other regulatory agencies around the world.
“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world,” said Bourla in a statement.
“With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world,” he added.